title: [Effects of Salidroside on Tic Behavior of Tourette Syndrome Model Rats].
abstract: OBJECTIVE
  To observe the effect of salidroside on tic behavior and in vivo dopamine DA) and serotonin (5-HT) levels in Tourette syndrome (TS) model rats.
  
  
  METHODS
  Forty rats were randomly divided into the blank control group, the TS model group, the haloperidol-treated group (0.5 mg/kg x d(-1)), and the salidroside-treated group (50 mg/kg x d(-1)), 10 in each group. TS rat model was induced by imino-dipropio-nitrile (IDPN). Peritoneal injection of haloperidol and salidroside was started from the 4th day of modeling in the haloperidol-treated group and the salidroside-treated group respectively. Normal saline was peritoneally injected to rats in the blank control group and the TS model group respectively. Stereotyped behavior was scored, and changes of DA and 5-HT levels in blood and striatum were measured before modeling, after modeling, and after intervention.
  
  
  RESULTS
  Compared with the blank control group, the score of the tic behavior was elevated (P < 0.01) , levels of DA and 5-HT in plasma and striatum were reduced in the model group (P < 0.01, P < 0.05). Compared with the same group after modeling, the tic behavior score decreased and plasma DA levels increased in the two treated groups after intervention (P < 0.01). 5-HT content increased in the salidroside-treated group (P < 0.01). Compared with the model group after intervention, the tic behavior score was significantly reduced (P < 0.01), and DA levels in plasma and striatum were elevated (P < 0.01, P < 0.05) in the salidroside-treated group and the haloperidol-treated group. Compared with the haloperidol-treated group, the tic behavior score increased (P < 0.01), DA levels in plasma and striatum were lowered (P < 0.01, P < 0.05), the 5-HT level increased in plasma and striatum (P < 0.01, P < 0.05) in the salidroside-treated group.
  
  
  CONCLUSIONS
  In the salidroside-treated group, the tic behavior was significantly reduced, and DA levels in plasma and striatum were elevated. Its mechanism might be related to regulating activities of dopamine neurons in striatum.
authors.forename: Hui
authors.initials: H
authors.lastname: Xie
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Ji
authors.forename: Jing
authors.initials: J
authors.lastname: Yin
authors.forename: Wen-hao
authors.initials: WH
authors.lastname: Yang
authors.forename: Li-min
authors.initials: LM
authors.lastname: Ren
mesh_terms: D000818:Animals; D003342:Corpus Striatum; D004298:Dopamine; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005960:Glucosides / Q000494:pharmacology / Q000627:therapeutic use*; D006220:Haloperidol; D010636:Phenols / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012701:Serotonin; D013239:Stereotyped Behavior; D020323:Tics / Q000188:drug therapy*; D005879:Tourette Syndrome / Q000188:drug therapy*
chemical_list: D004365:Drugs, Chinese Herbal; D005960:Glucosides; D010636:Phenols; D012701:Serotonin; D006220:Haloperidol; C009172:rhodioloside; D004298:Dopamine